[60]Fullerene-peptides: bio-nano conjugates with structural and chemical diversity by Andrew, Barron
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in :
Journal of Enzyme Inhibition and Medicinal Chemistry
                                                       
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa28915
_____________________________________________________________
 
Paper:
Barron, A. (2016).  [60]Fullerene-peptides: bio-nano conjugates with structural and chemical diversity. Journal of
Enzyme Inhibition and Medicinal Chemistry, 1-13.
http://dx.doi.org/10.1080/14756366.2016.1177524
 
 
 
 
 
 
 
 
_____________________________________________________________
  
This article is brought to you by Swansea University. Any person downloading material is agreeing to abide by the
terms of the repository licence. Authors are personally responsible for adhering to publisher restrictions or conditions.
When uploading content they are required to comply with their publisher agreement and the SHERPA RoMEO
database to judge whether or not it is copyright safe to add this version of the paper to this repository. 
http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/ 
 J. Enzyme Inhib. Med. Chem. 
1 
[60]Fullerene-Peptides: Bio-Nano Conjugates with Structural and 
Chemical Diversity  
Andrew R. Barron* 
1Department of Chemistry, Rice University, Houston, TX 77005, USA, 2Department of 
Materials Science and Nanoengineering, Rice University, Houston, TX 77005, USA, 3College 
of Engineering, Swansea University, Bay Campus, Swansea SA1 8QQ, Wales, UK, 4Centre 
for Nanohealth, Swansea University, Singleton Park, Swansea SA2 8PP, Wales, UK.  
Corresponding author. E-mail: a.r.barron@swansea.ac.uk; arb@rice.edu  
 
Keywords: C60, amino acid, hydrophilic, HIV, cell, membrane 
 
 
J. Enzyme Inhib. Med. Chem. 
2 
Fullerene-Peptides: Bio-Nano Conjugates with Structural and Chemical 
Diversity 
[60]Fullerene-peptides represent a simple yet chemically diverse example of a bio-nano 
conjugate. The C60 provide the following attributes to the conjugate: a) precise three-
dimensional architecture, b) a large hydrophobic mass, and c) unique electronic 
properties. Conversely, the peptide component provides: a) structural diversity depending 
on the overall length and amino acids composition, b) charge flexibility, and c) secondary 
structure and recognition. Recent advances in the synthetic strategy for [60]fullerene-
peptide synthesis from both pre-formed peptides and using solid phase peptide synthesis 
(SPPS) are described. The effects of the hydrophobic C60 on the secondary structure of 
the peptide depend on the sequence of the latter, but in general the relative stability of 
particular structures is greatly enhanced. The ability of the [60]fullerene substituent to 
dramatically modify the both cellular uptake and transdermal transport is discussed as is 
the effects on cell viability and antimicrobial activity.  
Introduction 
The discovery of the first fullerene compound C60 is a pivotal moment in modern chemistry (1). 
Not only was it the discovery of a new form of elemental carbon, it also provided the archetype 
linkage between the molecular and nano regimes. No sooner was the discovery published than 
a plethora of researchers initiated studies of the physical and chemical properties of C60, as well 
as its higher homologs (e.g., C70), but also its elongated relatives (carbon nanotubes) (2). One 
feature of these materials that was quickly apparent was their extreme hydrophobic nature (3), 
which suggested limited biological implications due to the restricted transport in aqueous 
solution (4). However, it was this same hydrophobicity coupled with the electrochemical 
behaviour (5) that offered an interesting potential for interactions with biological systems 
(6,7,8).  
Initial studies of the biological activity of fullerenes involved functionalization designed 
to enhance the solubility (7, 9), which involved chemical substituents with acid or basic groups 
to allow either the formation of charged species in water at relevant pH or enhanced hydrogen 
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bonding (10). A logical extension of this approach was the formation of zwitter ionic 
functionality, and it is here that amino acid moiety represents a flexible solution to solubility 
and functionality. The presence of potentially both positive (-NH3
+) and negative (-CO2
-) 
functionality offers compatibility in aqueous solutions over a range of pH and ionic 
concentration, while the inherent chemical functionality allows for their use as synthons to 
create larger structures. The first amino acid derivative of C60 was reported in 1993 (11), and 
since that time [60]fullerene amino acids have been prepared with a variety of linkage units 
(12-16). Figure 1 shows an idealized structure of a C60-amino acid, where the linkage unit may 
or may not be either structurally related to a known amino acid, and can vary in its flexibility 
and length. The topic of [60]fullerene amino acids has been reviewed (17,18).  
Given the composition of a peptide is a polymer of various amino acids, one obvious 
application of [60]fullerene-based amino acids is their incorporation into a peptide chain. The 
resulting [60]fullerene-peptide conjugate represents possibly the simplest, but chemically and 
structurally most flexible, bio-nano conjugate. The [60]fullerene moiety provides the following 
attributes to the conjugate: a) precise three-dimensional architecture, b) a large hydrophobic 
mass, and c) unique electronic properties (17). In contrast, the peptide component provides: a) 
structural diversity depending on the overall length and amino acids composition, b) charge 
flexibility, and c) secondary structure and recognition. There is also the potential that the 
presence of the hydrophobic [60]fullerene will modify the properties of the peptide and as such 
behavior unlike either of the component parts is possible.  
The topic of [60]fullerene-peptide derivatives has been reviewed (17-20); however, 
recent results have shown the versatility of both synthetic methods and applications, and 
suggest that a fresh view is warranted.  
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Synthesis of C60-peptide conjugates 
Conceptually, there are two synthetic routes to the formation of [60]fullerene-peptide 
conjugates. The simplest is to functionalize [60]fullerene with a preformed peptide, while more 
challenging synthetically is to perform peptide synthesis where the [60]fullerene component is 
introduced as a non-natural amino acid in the peptide sequence.  
Using a preformed peptide 
The direct reaction of a suitably functionalized peptide chain with C60 was first reported by 
Romanova et al. (21). Using the high nucleophilicity of the primary amine in natural amino 
acids, reaction of C60 with various dipeptide derivatives (L-Ala-L-Ala, D,L-Ala-D,L-Ala, and 
Gly-L-Val) occurred via nucleophilic addition (Figure 2). As an alternative, Wang et al. (22) 
showed that methyl glycylglycinate (H-Gly2-OMe) reacted via a nitrene intermediate (formed 
in the addition of Br2) with C60 to form the dipeptide derivative (Figure 2). The use of a phase 
transfer overcame the issues associated with the low solubility of C60 in water.  
 The first [60]fullerene peptide was prepared by the reaction of a N-terminal free 
pentapeptide (Ala-Aib-Ala-Aib-Ala-OMe) with a methanofullerene through a linker based on 
a benzoic acid moiety (Figure 3) (23). Following this report a wide range of alternative linkage 
groups have been reported as being equally effective in facilitating the attachment of a 
preformed peptide (24-30). Much of this work has been subject to recent reviews (17-20), and 
a selection of the [60]fullerene derivatives used are also shown in Figure 3. One important route 
that was demonstrated with the immunomodulating peptide tuftsin (Thr-Lys-Pro-Arg) allowed 
for the covalent conjugate to be formed via either reaction with the amine or carboxylic acid 
termini (Figure 4), which provides a flexibility to attach further substituents.  
 Although it had been found that it is possible to insert a preformed [60]fullerene-amino 
acid into the center of a peptide during solid phase peptide synthesis (31), an alternative 
approach was reported, by Aroua et al., using a bis-tert-butyl ester (Figure 5) that was reacted 
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with resin-supported peptide to give a fulleropeptide (32). Of course the difference between 
this approach and that described below is that this method results in the same CO2H termination 
at both ends of the resulting peptide. Thus, the latter may be better described as two peptides 
located on the same [60]fullerene.  
Simultaneous peptide synthesis 
With this route, the goal is to synthesis a [60]fullerene substituted amino acid that can react in 
a similar manner to any other amino acid and undergo polymerization, with other (naturally 
occurring) amino acids. In this manner, the [60]fullerene amino acid residue can be positioned 
at the end or within the resulting peptide chain. A further advantage of performing the reaction 
by solid phase peptide synthesis (SPPS) is that unlike solution phase methods, the purification 
process is much simpler. However, it is necessary to prepare C60-derived amino acids suitable 
for subsequent reaction (14). Several suitable [60]fullerene derived amino acids have recently 
been reported, see Figure 6 (15,16,31,33).  
The synthesis of a [60]fullerene peptide by SPPS was initially achieved using Fmoc (9-
fluorenylmethoxycarbonyl protected) chemistry (14,34). The classical deprotection agent for 
the Fmoc protecting group is piperidine, and while it was initially reported that this was 
successful, subsequent work demonstrated that this result was erroneous as piperidine forms 
multiple stable adducts with the [60]fullerene core. To overcome this problem, it was suggested 
that 5% DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) in DMF (dimethylformamide) was used for 
deprotection; however, great difficulty in obtaining a pure product even after HPLC purification 
results (35). It was shown that DBU interfers with mass spectrometry measurement and HPLC 
purification of the peptide. These difficulties led to the development of Boc (tert-
butyloxycarbonyl) protecting group chemistry (31,36). It is interesting to note that the success 
of a particular coupling reaction (Boc versus Fmoc) must depend on the identity of the linkage 
group between the C60 and the amino acid, since the Fmoc chemistry was found to be successful 
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for Aza-C60-Phe-OH (37), derived from the dipolar addition to C60 of the Fmoc-N-protected 
azido amino acids (16), but not for the [60]fullerene-substituted phenylalanine (Baa) prepared 
by cycloaddition (see Figure 6). It is unknown why an apparently small difference in the linkage 
group makes such a big difference in the reactivity.  
In order to study how the presence and position within the peptide sequence of the 
[60]fullerene affects the structure and relative structural stability of the peptide’s conformation, 
the sequences Glu-Ile-Ala-Gln-Leu-Glu-Tyr-Glu-Ile-Ser-Gln-Leu-Glu-Gln-NH2 (2HP) was 
prepared in which either Baa (Figure 6) was added to the terminus (i.e., Baa-Glu-Ile-Ala-Gln-
Leu-Glu-Tyr-Glu-Ile-Ser-Gln-Leu-Glu-Gln-NH2) or tyrosine (Tyr) was replaced with Baa (i.e., 
Glu-Ile-Ala-Gln-Leu-Glu-Baa-Glu-Ile-Ser-Gln-Leu-Glu-Gln-NH2). In addition, Baa was 
added to the terminus of Glu-Ile-Ala-Gln-Leu-Glu-Tyr-Glu-Ile-Ser-Gln-Leu-Glu-Gln-Glu-Ile-
Gln-Ala-Leu-Glu-Ser-NH2 (3HP) (i.e., Baa-Glu-Ile-Ala-Gln-Leu-Glu-Tyr-Glu-Ile-Ser-Gln-
Leu-Glu-Gln-Glu-Ile-Gln-Ala-Leu-Glu-Ser-NH2) (31). It was observed that the yield was 
lower and the purification more difficult when the [60]fullerene residue is within the sequence.  
In addition to the facilitating of higher yields when the [60]fullerene derivative is at the 
end, rather than in the middle of the peptide sequence, it has also been observed that the further 
the [60]fullerene residue was placed from the polymer matrix solid support the higher the 
isolated yield, see Figure 7 (34). The overall length of the peptide chain also seems to play a 
role, as the recovery of the short peptides is difficult even when the [60]fullerene amino acid is 
inserted at the N-terminus. It has been suggested that the presence of the [60]fullerene affects 
the swelling properties of the polymeric solid support. In contrast, use of the N-Boc-Baa 
chemistry has been shown to result in high yields of the Baa-terminated peptides independent 
of the length of the peptide (31). However, the yield of the [60]fullerene peptide does show a 
dependence on the hydrophobicity of the peptide sequence: the more hydrophilic the sequence, 
the higher the yield (31). 
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One of the most interesting developments is the synthesis of an all [60]fullerene amino 
acid derived peptide by Watanabe et al. (35). Given the problems reported for solid phase 
synthesis due to the tendency of the [60]fullerene to become embedded onto the resin making 
it difficult to recover the product in reasonable yield (14,34) solution synthesis was used to 
prepare unique multi-[60]fullerene peptides. Coupling H-Gly-OBzl (Bzl = CH2C6H5) to a 
functionalized [60]fullerene Fmoc-Af8-OH (Af8 = 2-amino-8-fulleropyrrolidinoalkanoic acid, 
see Figure 8a) followed by subsequent deprotection of the Fmoc group using 5% DBU in DMF 
resulted in the formation of bis-adduct of [60]fullerene. However, the use of the Boc method 
(using Boc-Af8-OH, Figure 8a) yielded Boc-Af8-Ala-OBzl. Deprotection of the Boc group 
with trifluoroacetic acid (TFA) allowed for coupling of the dipeptide benzyl ester with Boc-
Af8-OH to give Boc-(Af8)2-Ala-OBzl. Repetition of the deprotection and coupling steps gave 
the tetrapeptide Boc-(Af8)3-Ala-OBzl (Figure 8b).  
Finally an interesting footnote, since peptide biosynthesis offers a potential alternative 
to SPPS, the concept of creating an amino acylated 5’-phospho-2’-deoxyribocytidylribo-
adenosine subunit containing a [60]fullerene amino acid (pdCpA-Baa) was attempted (37). 
Unfortunately, no reaction was observed between the hydrophilic phospho-cytidine-phospho-
adenosine subunit (pdCpA) and hydrophobic Baa possibly due to the steric bulk of the latter.  
Structural effects 
The [60]fullerene containing peptides have been generally characterized by matrix assisted 
laser desorption/ionization (MALDI) mass spectrometry by the presence of the M+, M++H, or 
M++Na ions, depending on the reaction conditions (31,36). In some cases the [60]fullerene-
functionalized peptides are sufficiently soluble in H2O to provide a UV-visible spectrum (36), 
while IR spectroscopy shows the functionalization of the C60 (39). However, it is the effect of 
the hydrophobic C60 moiety on the peptide configuration that is of most interest.  
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In the earliest report of [60]fullerene peptides it was shown that the presence of the 
[60]fullerene had a significant effect on the secondary structure of the peptide (34). Circular 
dichroism (CD) analysis of a peptide H-Gly-(Nle)2-Gln-Orn-Nle-Gly-(Orn)2-Nle-(Orn)2-Nle-
Gly-(Orn)2-Nle-Gly-Tyr-NH2 (Figure 9a) indicates indicated that it is unstructured in aqueous 
solution but assumes a partly helical structure (∼40%) in the presence of the helix-promoting 
solvent, e.g., trifluoroethanol (TFE) or sodium dodecyl sulfate (SDS) (40). The shape of the 
CD spectra for fullero-peptides H-Fgu-Gly-(Nle)2-Gln-Orn-Nle-Gly-(Orn)2-Nle-(Orn)2-Nle-
Gly-(Orn)2-Nle-Gly-Tyr-NH2 and H-Gly-(Nle)2-Gln-Orn-Nle-Gly-(Orn)2-Fgu-(Orn)2-Nle-
Gly-(Orn)2-Nle-Gly-Tyr-NH2 (where Fgu = fulleropyrrolidino-glutamic acid, see Figure 6) 
instead indicates a significant degree of helix formation in aqueous solution (Figure 9b and c). 
Unlike the native peptide, the spectra for both fullero-peptides change distinctly in the presence 
of SDS micelles than of TFE (see Figure 9b and c). The shape of the spectrum for fullero-
peptide H-Gly-(Nle)2-Gln-Orn-Nle-Gly-(Orn)2-Fgu-(Orn)2-Nle-Gly-(Orn)2-Nle-Gly-Tyr-NH2 
changes in a manner consistent with the presence of an extended conformation (34).  
Although initial results suggested that the presence of a [60]fullerene substituent would 
change the relative stability of specific secondary structures, subsequent work showed that the 
[60]fullerene could either promote a different structure or preclude a structural change (31). For 
example while the parent peptide Glu-Ile-Ala-Gln-Leu-Glu-Tyr-Glu-Ile-Ser-Gln-Leu-Glu-
Gln-NH2 (2HP) adopts a random coil in aqueous solution, and is transformed via an α-helix to 
a β-sheet with decreasing pH, when the [60]fullerene amino acid Baa (Figure 6) is on the 
terminus (i.e., Baa-Glu-Ile-Ala-Gln-Leu-Glu-Tyr-Glu-Ile-Ser-Gln-Leu-Glu-Gln-NH2) the β-
sheet structure is observed at all pH values. In contrast, with the Baa in the middle of the peptide 
(i.e., Glu-Ile-Ala-Gln-Leu-Glu-Baa-Glu-Ile-Ser-Gln-Leu-Glu-Gln-NH2) the random coil 
converts to an α-helix with decreasing pH, but never to a β-sheet (31). By contrast, the longer 
sequence Baa-Glu-Ile-Ala-Gln-Leu-Glu-Tyr-Glu-Ile-Ser-Gln-Leu-Glu-Gln-Glu-Ile-Gln-Ala-
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Leu-Glu-Ser-NH2 maintains an α-helix structure over all pH studied, while the parent is 
observed as a random coil in aqueous solution that converts to an α-helix with decreasing pH. 
It is thus clear that while the [60]fullerene has a significant effect of secondary structure there 
is no consistent effect, and further study will be important.  
It has been observed that while [60]fullerene-peptides are soluble in water they form 
aggregates, presumably as a consequence of the presence of both hydrophobic (C60) and 
hydrophilic (amino acid) groups within the same molecule (31). The relative size of the 
aggregates is found to depend on the pH of the solution, but independent of concentration. The 
[60]fullerene peptide Baa-Lys(FITC)-Lys8-OH (FITC = fluorescein isothiocyanate) forms 
spherical and ellipsoidal cluster (average = 40-80 nm); however, upon addition of 10% SDS in 
PBS (phosphate-buffered saline), 100 nm diameter nano-tubule structures are formed, which in 
turn align to form bundles (Figure 10).  
The self-assembling properties and morphology of [60]fullerene peptides of different 
chain lengths in comparison with the native amino acid have been studied using scanning 
electron microscopy (SEM) (29). Figure 11a shows a comparison of the self-organized 
structures of the tert-butyl ester of the parent [60]fullerene amino acid, Fp-GABA-OtBu (c.f. 
Figure 3, GABA = γ-aminobutyric acid) and the steroid derivative (Fp-GABA-OSt, Figure 11b) 
with those of the [60]fullerene peptidosteroid hybrids, Fp-GABA-Gly-GABA-OSt and Fp-
GABA-GABA-Gly-GABA-OSt, Figure 11c and d, respectively. The shorter [60]fullerene 
peptidosteroid hybrid formed hierarchically organized, branched network of well-arranged rods 
(Figure 11c). Increasing the length of the peptide resulted in the formation of unordered slightly 
curled microsheets (Figure 11d). It was proposed that the supramolecular assembly is 
influenced by a balance between: 1) π-stacking interactions of the [60]fullerene moiety, 2) the 
hydrophobic interactions of the steroid unit, 3) the participation of the hydrogen bonding, and 
4) van der Waals interactions associated with peptide chain and steroid moiety. 
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Antioxidant activity 
The antioxidant activity C60 and its derivatives are well established, but low solubility and a 
tendency to aggregation are considered limiting factors of its application. The antioxidant assay 
of Baa (Figure 6) and the derived peptide, Baa-(Glu)4-(Gly)3-Ser-OH were determined in 
comparison with Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), a 
commercially available potent antioxidant of the vitamin E family (31). As may be seen from 
Figure 12, the parent amino acid is a very potent antioxidant with an IC50 of 55.88 M, i.e., 
about 10 times more potent than Trolox. The linear relation for the inhibition versus 
concentration is consistent with the electrochemical behavior of [60]fullerene amino acids 
showing the ability of the C60 core to accept multiple electrons (31). The IC50 of Baa-(Glu)4-
(Gly)3-Ser-OH was determined to be 89 M. It is unclear why there is a slight reduction in 
activity between Baa and the Baa-containing peptide. It is possible that aggregation of the Baa-
peptide acts as a buffer limiting electron transfer processes. However, what was interesting was 
that [60]fullerene peptides with cationic sequences show no antioxidant activity.  
 In a different study, the antioxidant capacity was measured by the ferrous ion oxidation-
xylenol orange (FOX) method for [60]fullerene peptidosteroid hybrids, Fp-GABA-Gly-
GABA-OSt and Fp-GABA-GABA-Gly-GABA-OSt (Figure 11c and d, respectively) (29). As 
may be seen from Figure 13, there is significant improvement over vitamin C and C60 (29). This 
was suggested to be associated with reduced aggregation and high solubility of the peptide 
derivatives.  
Cellular uptake 
The incubation of human embryonic kidney (HEK-293) cells with Lys(FITC)-(Lys)8-OH and 
Baa-Lys(FITC)-(Lys)8-OH revealed that while the cationic peptide shows no ability to cross 
over the cell membrane, the addition of [60]fullerene amino acid (Baa, Figure 6) to the sequence 
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facilitates the intracellular localization of the peptide (36). A similar result is obtained for the 
non-fullerene phenylalanine substituted nuclear localization sequence (NLS) derivative (Phe-
Lys(FITC)-(Lys)2-Arg-Lys-Val-OH) that shows no uptake into HEK-293 cells, but Baa-
Lys(FITC)-(Lys)2-Arg-Lys-Val-OH not only exhibts uptake, but concentration in the nuclei of 
the cells (36). This results suggested that the presence of a nuclear localization sequence results 
in transport across the nuclear membrane. Neuroblastoma cells are known for their difficulty in 
transfection through the cell membrane. However, incubation of H-Baa-Lys(FITC)-(Lys)2-Arg-
Lys-Val-OH with human IMR-32 cells and treating with 4',6-diamidino-2-phenylindole 
(DAPI) nuclei staining dye (Figure 14) show intense point fluorescence in cytoplasm, and 
homogeneous intense fluorescence around nuclei closely associated with the blue of the DAPI 
nuclei staining dye. Additional studies showed that the uptake intensity for the anionic peptide 
Baa-Lys(FITC)-(Glu)4-(Gly)3-Ser is greatly reduced in comparison with the cationic 
[60]fullerene peptides of the same concentration. The cellular uptake is also decreased by the 
addition of increasing concentrations of -cyclodextrin (CD). 
 Given the ability of [60]fullerene-peptides to facilitate intra celluar transport (36), the 
mechanism of uptake of the poly-lysine derivative with a FITC label (Baa-Lys(FITC)-(Lys)8-
OH) was investigated (41). Baa-Lys(FITC)-(Lys)8-OH was found to be present near the cell 
membrane at 15 min and entered into the cytoplasm by 30 min but did not localize in the 
lysosomes. Endocytic inhibitors showed that the endocytic pathways could be mediated by 
caveolae/lipid rafts and cytoskeletal components. A scavenger receptor inhibitor completely 
blocked the uptake of Baa-Lys(FITC)-(Lys)8-OH, suggesting a specific endocytic pathway was 
strongly involved in Baa-Lys(FITC)-(Lys)8-OH cellular uptake (41).  
Toxicity and antimicrobial activity 
The functionalization of C60 has the potential to provide greater interaction between the 
[60]fullerene and the biological environment yielding potential new medical and 
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pharmacological applications; however, there is equal concern over the potential toxicity of any 
such conjugate. Studies had shown that exposure of human epidermal keratinocytes (HEK) to 
the amino acid Baa (Figure 6) resulted in a decrease of the MTT cell viability after 48 h 
significantly decreased only for concentrations of >0.04 mg/mL (42). In addition, human 
cytokines IL-6, IL-8, TNF-α, IL-1b, and IL-10 were assessed, and indicated that at 
concentrations lower than 0.04 mg/mL cell viability is maintained.  
 Introduction of a [60]fullerene amino acid (Fgu, Figure 6) at the N-terminus of H-Gly-
(Nle)2-Gln-Orn-Nle-Gly-(Orn)2-Nle-(Orn)2-Nle-Gly-(Orn)2-Nle-Gly-Tyr-NH2 was shown to have a 
dramatic effect on both the antimicrobial activity of the peptide sequence (34). The activity is 
considerably reduced for E. coli and C. albicans, but increased for S. aureus, upon inclusion of 
the [60]fullerene. A similar behavior was observed for H-Gly-(Nle)2-Gln-Orn-Nle-Gly-(Orn)2-
Fgu-(Orn)2-Nle-Gly-(Orn)2-Nle-Gly-Tyr-NH2, where the [60]fullerene-based residue is positioned 
in the middle of the sequence. However, it was shown that the antimicrobial activity was most 
probably inherently due to the C60 rather than the specific sequence, since the fullero-peptide 
H-Gly-Orn-Gly-Fgu-Gly-Orn-Gly-NH2 showed equal or better activity (34). The presence of C60 
itself is clearly not totally a prerequisite for antimicrobial activity since, in a study of a series 
of [60]fullerene peptide derivatives, tested using the broth microdilution method against 
Staphylococcus aureus NCTC 6571 and Escherichia coli NCTC 10418, all the fullerenyl-based 
compounds were inactive, even at higher concentrations, with MIC greater than 100 to 340 
(μg/mL) (28).  
 Possibly the result that is both disappointing and promising at the same time, is a study 
of a series of [60]fullerene-peptides, based upon Baa (Figure 6), with range of cell lines. 
Exposure of SH-SY5Y neuroblstoma cells to the Baa-peptides for 48 hrs showed no significant 
inhibition of cell growth by Baa-Lys(FITC)-Asn-Asp-Leu-Arg-Ser-Ser-Phe-Leu-Thr-Leu-
Arg-Asp-His-Val (Baa-1) or Baa-Lys(FITC)-Asn-Asp-Leu-Arg-Ser-Ser-Phe-Ala- Thr-Leu-
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Arg-Asp-His-Val (Baa-2) nor the parent peptides. However, whereas the peptide Phe-
Lys(FITC)-Asn-Asp-Leu-Arg-Ser-Ala-Phe-Ala-Thr-Leu-Arg-Asp-His-Val showed no 
inhibition, the Baa derivative (Baa-Lys(FITC)-Asn-Asp-Leu-Arg-Ser-Ala-Phe-Ala-Thr-Leu-
Arg-Asp-His-Val, Baa-3) showed significant inhibition towards this cell line at 40 µM. This 
initial result suggested that with the right combination of the [60]fullerene and the sequence 
controlled inhibition was possible (43).  
A much more unexpected result was observed when the inhibitory effects of the Baa 
peptides and their parent peptides were tested against the proliferation of neuroblastoma cell 
lines IMR-32 and LAN-1 and breast cancer cell line MCF-7. While neither the parent peptides 
(Phe-Lys(FITC)-Asn-Asp-Leu-Arg-Ser-Ser-Phe-Leu-Thr-Leu-Arg-Asp-His-Val and Phe-
Lys(FITC)-Asn-Asp-Leu-Arg-Ser-Ala-Phe-Ala-Thr-Leu-Arg-Asp-His-Val) showed 
significant inhibitory effects, their Baa peptide conjugate activated the proliferation of these 
cells (Figure 15). Although the underlying cause of this activation process was not explained 
(43), this effect if observed with other cell lines might constitute a possible therapeutic approach 
for degenerative illnesses where cell growth is haltered. 
Antibody recognition  
As noted in the introduction, one of the attributes of a peptide is its ability to be recognized. 
However, the question is whether the presence of a [60]fullerene disrupts or enhances this 
recognition? It is natural therefore to investigate whether an antibody would recognize an 
antigen peptide sequence when a [60]fullerene was present on the peptide.  
Sofou et al. have reported the synthesis of a C60-peptide (containing a solubilizing 
ethyleneglycol appendage) based upon the heptapeptide, H-(Pro)2-Gly-Met-Arg-(Pro)2-OH, 
which had been previously shown to have anti-genic properties (30). This proline-rich 
heptapeptide has been found to be the main target of the anti-Sm and anti-U1RNP 
autoantibodies in sera of patients with autoimmune diseases such as systemic lupus 
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erythematosus (SLE) and mixed connective tissue disease (MCTD). It was also found that the 
H-(Pro)2-Gly-Met-Arg-(Pro)2-OH epitope is recognized by anti-Ro/La positive sera, although 
they are negative for anti-Sm and anti-U1RNP (30). The [60]fullerene peptide (Figure 16), with 
oxidized methionine, was evaluated in comparison with the parent fulleropyrrolidine (Figure 
3) for their ability to recognize anti-Sm and anti-U1RNP autoantibodies in SLE and MCTD 
patients’ sera (ELISA experiment). In Table 1, the reactivities of the [60]fullerene peptide are 
listed in comparison with the parent peptide in its free and C-terminal amide form.  
While the [60]fullerene-peptide strongly recognizes anti-Sm/U1RNP specificities, it 
was also recognized by anti-Ro/La positive sera, which are negative to anti-Sm/U1RNP sera. 
Most importantly, the parent [60]fullerene compound shows no recognition at all, suggesting 
that conversion of the carboxylic end of the parent peptide to an ester functionality in the 
[60]fullerene peptide was responsible for the decrease in disease specificity.  
Enzymatic inhibition and anti-HIV activity 
Immunomodulating peptide tuftsin (Thr-Lys-Pro-Arg) derivatives of C60 (Figure 11) were 
assayed for their stability against leucine aminopeptidase degradation and the immunostimulant 
activity to murine peritoneal macrophages were investigated in vitro (27). Compared with the 
natural tuftsin, both [60]fullerene derivatives showed significant enhancement of phagocytosis, 
chemotaxis activities and major histocompatibility complex class II (MHC II) molecule 
expression. The two conjugates also exhibit complete resistance to enzymatic hydrolysis, and 
were found to be non-toxic to macrophages in the tested concentrations. These results suggested 
that the C60–tuftsin conjugates could be used as potential candidates of immune modulators and 
vaccine adjuvants (27).
 
The active site of the HIV-1 protease (HIV-1 PR) is a quasi-spherical hydrophobic 
cavity, whose diameter is about 10 Å. In a landmark paper Friedman et al., suggested from 
computer graphics simulation, that the hydrophobic cleft of HIV-1 protease could perfectly host 
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a C60 molecule (44). If the interaction between the C60 and HIV-1 PR could be made sufficiently 
strong, inhibition of the catalytic activity would be expected. However, the problem of 
solubilizing C60 in a medium suitable for biological tests was initially an issue since it is 
insoluble in water. Given the solubility of [60]fullerene-peptide conjugates it was suggested 
that these would be ideal candidates for HIV-1 inhibition (24). 
 
Unfortunately, initial results were unpromising. Anti-HIV-1 protease activities were 
conducted on using a [60]fullerene conjugate of the pentapeptide sequence H-Thr-Thr-Asn-
Tyr-Thr-OH (Figure 17), since this sequence is a known activator of human monocyte 
chemotaxis; however, the activity was shown to be moderate (Ki = 100 μM) (24). Some promise 
was given since the [60]fullerene-peptide activity was elevated compared to the underivatized 
peptide.  
In an effort to narrow the plethora of possible “C60 fragment” and “peptide sequence” 
combinations an in silico drug screening approach was investigated (45). A database was 
created from a range of C60 derivatives and their binding scores with HIV-1 PR were computed 
using docking techniques, and compared with biological tests with purified HIV-1 PR. It was 
interesting that experimental results confirm the binding scores predicted from the docking 
calculations. From this data it was found that Fmoc-Baa (c.f. Figure 6) had about three times 
better inhibitory binding (Ki = 36 nM) than the most active [60]fullerene-based inhibitor (Ki = 
103 nM) reported at that time (45). The calculations also suggested that the presence of the 9-
fluorenylmethoxycarbonyl (Fmoc) protecting group on the [60]fullerene-substituted 
phenylalanine (i.e., Fmoc-Baa) improved the inhibition dramatically as compared to the 
corresponding free amino acid (Baa, Figure 6) because of a favorable interactions with the 
hydrophobic binding pocket (45). In order to determine if improved binding was possible 
through the incorporation of a designer peptide tail, a series of [60]fullerene amino acid derived 
peptides were prepared (37). In this case the terminal amino acid, Phe(4-aza-C60)-OH, was 
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derived from the dipolar addition to C60 of the Fmoc-N-protected azido amino acids derived 
from phenylalanine (16).  
The rationale for the design of three peptide models was based on the structure of HIV-
1 PR itself. It was hypothesized that an oligo-Lys peptide tail (Figure 18a) would provide both 
the positive charges and enough flexibility for the electrostatic interaction to occur (45). The 
knowledge that HIV-1 PR can recognize a Phe-Pro dipeptide subunit was the rationale for 
choosing a Pro-Hyp-Lys sequence (Figure 18b), and the Hyp-Hyp-Lys sequence (Figure 18c) 
was chosen because the addition of the second OH group present on Hyp (as compared to Pro) 
allows another opportunity for H-bonding (37). The position of the [60]fullerene peptides into 
the active site were determined in silico (Figure 19) and compared to the binding 
experimentally. The experimental results showed that all of the peptide derivatives showed 
improved inhibition over the C60 amino acid base; however, none were as effective as the most 
potent inhibitor reported previously, i.e., Fmoc-Baa-OH (45). The most active of the peptide 
inhibitors was Fmoc-Phe(4-aza-C60)-Hyp-Hyp-Lys-OH with two hydroxyproline residues (Ki 
= 76); which is much more active than Fmoc-Phe(4-aza-C60)-Pro-Hyp-Lys-OH (Ki = 120), with 
only one hydroxyproline residue. It is unknown if the observed increase in binding affinity was 
due to better placement of the second hydroxyl moiety in regards to the aspartyl residues or if 
it is was due to the increase in H-bonding opportunities; however the difference in energy is 
worth approximately that of a H-bond. 
Recent quantitative structure–activity relationship models (QSAR) and docking 
calculations have shown that [60]fullerene derivative with two O atoms and an additional 
hydroxymethylcarbonyl (HMC) group has good HIV-1 protease inhibitory properties (46). The 
resulting balance between hydrophobic and hydrogen bonding was discussed, and in 
combination with the results observed for the [60]fullerene-peptides should guide the future 
direction of this research.  
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Transdermal effects 
The ability of nanomaterials (such as quantum dots and fullerenes) to penetrate intact skin 
(47,48) can be either a concern with regard to toxicity or provide a route for drug delivery. 
Given that the addition of a [60]fullerene-derived amino acid to a cationic peptide results in the 
peptide showing cellular uptake, whereas the same peptide sequence in the absence of Baa 
shows no transport across the cell membrane (36), it was logical to investigate whether the same 
[60]fullerene-peptides could facilitate transdermal transport. Dermatomed porcine skin was 
fixed to a flexing device and topically dosed with an aqueous solution of a [60]fullerene-
substituted phenylalanine (Baa, Figure 6) derivative of a nuclear localization peptide sequence, 
Baa-Lys(FITC)-NLS (NLS = Pro-Lys-Lys-Lys-Arg-Lys-Val) (49). The skin was flexed or left 
unflexed (control) and confocal microscopy demonstrated that dermal penetration of the 
nanoparticles at 8 h in skin flexed for at least 60 min (Figure 20). In contrast, Baa-Lys-(FITC)-
NLS did not penetrate into the dermis of unflexed skin until 24 h. Thus, flexing has a significant 
effect on the uptake.  
Although the mechanisms by which the flexing increases nanoparticle penetration was 
not determined, dynamic light scattering (DLS) and transmission electron microscopy (TEM) 
analyses found that in solution Baa-Lys(FITC)-NLS forms spherical and ellipsoidal clusters 
with average aggregate sizes of approximately 40-250 nm. Given that the vertical and lateral 
gaps between corneocytes present in the stratum corneum are about 19 nm (50) it suggested 
that the Baa-Lys(FITC)-NLS aggregates would be unlikely to diffuse through the epidermal 
layers via intercellular spaces. It is evident from the results of this study, however, that the 
[60]fullerene-based peptides do penetrate through the epidermal layers via passive diffusion 
and that flexing increases this penetration. TEM analysis revealed [60]fullerene-peptide 
localization within the intercellular spaces of the stratum granulosum. Clearly, further studies 
of the effects of different peptide sequences would be necessary in order to create a better 
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understanding of the mechanism of transdermal transport.  
Conclusions 
The recent work on [60]fullerene-peptides has shown their potential application across a wide 
range of applications. Some of these are expected, such as their antioxidant properties. 
However, the ability of the C60 moiety to facilitate cellular uptake and transdermal transport 
where the analogous parent peptides show no propensity, demonstrates the new chemistry 
observed for the conjugate as compared to the components. The understanding of the effects of 
such a compact superhydrophobic moiety within a biological system is only now being 
explored, and the use of computer simulation offers a real opportunity to screen many possible 
structures.  
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Table 1. Reactivity of sera containing various auto-antibodies (30).  
Derivative Anti-Sm/U1RNP (+) anti-
Ro/La (-)   
(%) 
Anti-Ro/La  (+) anti-
Sm/U1RNP (-) 
  (%) 
H-PPGMRPP-OH 75 40 
H-PPGMRPP-NH2
 75 17 
Fullero-peptide a 92 100 
Fullero-pyrrolidine b 0 0 
a See Figure 16. b See Figure 3.  
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Figure captions 
 
Figure 1. A schematic representation of an idealized [60]fullerene amino acid.  
 
Figure 2. Synthesis of C60-dipeptide conjugates via either nucleophilic addition or a nitrene 
intermediate (21,22).  
 
Figure 3. [60]fullerene derivatives used for the attachment of a preformed peptide. 
 
 
Figure 4. Two routes to the C60 conjugate with the immunemodulating peptide tuftsin (Thr-
Lys-Pro-Arg), yielding (a) NH2–tuftsin–C60 and (b) C60–tuftsin–CO2H (27). Boc = tert-
butyloxycarbonyl, Pbf = 2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl, EDC = 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide, HOBT = 1-hydroxybenzo-triazole, DIEA = 
diisopropylethylamine, DMF = dimethyl sulfoxide, DCM = dichloromethane, TFA = 
trifluoroacetic acid, TIS = triisopropylsilane, HBTU = O-benzotriazole-N,N,N′,N′-tetramethyl-
uronium-hexafluoro-phosphate, DBU = 1,8-diazabicyclo[5,4,0]undecen-7-ene. 
 
 
Figure 5. Reaction of bis-carboxylic acid [60]fullerene derivative with resin supported peptide, 
NH2-GABA-GPLGVRGA-CO2-resin (GABA = γ-aminobutyric acid) to provide a 
fulleropeptide (32).  
 
Figure 6. Selection of [60]fullerene amino acid derivatives.  
 
Figure 7. Plot of the recovered yield of crude peptide in the cleavage step as a function of the 
distance of the [60]fullerene-based residue (Fgu = fulleropyrrolidino-glutamic acid, see Figure 
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6) from the resin. Data from reference 34.  
 
Figure 8. The [60]fullerene Fmoc-Af8-OH (Af8 = 2-amino-8-fulleropyrrolidinoalkanoic acid 
(a) and a computer model of tetrapeptide Boc-(Af8)3-Ala-OBzl (b). Adapted with permission 
from Watanabe LA, Bhuiyan MPI, Jose B, Kato T, Nishino N. Synthesis of novel [60]fullerene 
amino acids and their multi-[60]fullerene peptides. Tetrahedron Letters, 2004;45:7137-7140. 
Copyright (2004) Elsevier Ltd. 
 
Figure 9. CD spectra of peptide H-Gly-(Nle)2-Gln-Orn-Nle-Gly-(Orn)2-Nle-(Orn)2-Nle-Gly-
(Orn)2-Nle-Gly-Tyr-NH2 (a) and the corresponding fullero-peptides H-Fgu-Gly-(Nle)2-Gln-
Orn-Nle-Gly-(Orn)2-Nle-(Orn)2-Nle-Gly-(Orn)2-Nle-Gly-Tyr-NH2 (b) and H-Gly-(Nle)2-Gln-
Orn-Nle-Gly-(Orn)2-Fgu-(Orn)2-Nle-Gly-(Orn)2-Nle-Gly-Tyr-NH2 (c) at 4 × 10-5 M 
concentration, in aqueous 5 mM phosphate buffer (pH 7) (…) or in the presence of 50% TFE 
(_.._) or 10 mM SDS (s) in phosphate buffer (---). Fgu = fulleropyrrolidino-glutamic acid, see 
Figure 6. Reprinted with permission from Pantarotto D, Bianco A, Pellarini F, Tossi A, 
Giangaspero A, Zelezetsky I, Briand JP, Prato M. Solid-phase synthesis of [60]fullerene-
peptides. J Am Chem Soc 2002;124:12543-12549. Copyright (2002) American Chemical 
Society. 
 
Figure 10. TEM micrographs of the aggregates formed by Baa-Lys(FITC)-Lys8-OH (a) in PBS 
buffer (1 mg.mL-1 @ pH=7) and (b) with 10% SDS in PBS buffer. Scale bars = 200 and 50 nm, 
respectively. Adapted with permission from Yang Y, Alemany LB, Driver J, Hartgerink JD, 
Barron AR. Fullerene-derivatized amino acids: synthesis, characterization, antioxidant 
properties, and solid phase peptide synthesis. Chem Eur J 2007;3:2530-2545. Copyright (2007) 
Wiley-VCH Verlag Gmbh & Co. 
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Figure 11. SEM images of the self-organized structures of (a) Fp-GABA-OtBu, (b) Fp-GABA-
OSt and [60]fullerene peptidosteroid hybrids (c) Fp-GABA-Gly-GABA-OSt and (d) Fp-
GABA-GABA-Gly-GABA-OSt, upon evaporation from a 9:1 PhMe/MeOH mixture deposited 
on glass substrate at room temperature and their 3D-structures. Scale bars correspond to 5 μm. 
Reproduced with permission from Bjelaković MS, Kop TJ, Vlajić M, Ðorđević J, Milić DR, 
Design, synthesis, and characterization of fullerene-peptide-steroid covalent hybrids. 
Tetrahedron 2014;70:8564-8570. Copyright (2014) Elsevier Ltd.  
 
Figure 12. Plot of inhibition (%) as a function of reagent concentration for antioxidant activity 
comparison using (a) Baa, (b) Baa-(Glu)4-(Gly)3-Ser-OH, and (c) Trolox. Adapted with 
permission from Yang Y, Alemany LB, Driver J, Hartgerink JD, Barron AR. Fullerene-
derivatized amino acids: synthesis, characterization, antioxidant properties, and solid phase 
peptide synthesis. Chem Eur J 2007;3:2530-2545. Copyright (2007) Wiley-VCH Verlag Gmbh 
& Co.  
 
Figure 13. Comparison of the antioxidant capacities of Fp-GABA-Gly-GABA-OSt and Fp-
GABA-GABA-Gly-GABA-OSt (Figure 11c and d, respectively) with regard to vitamin C and 
C60 measured by FOX assay. Adapted with permission from Bjelaković MS, Kop TJ, Vlajić M, 
Ðorđević J, Milić DR, Design, synthesis, and characterization of fullerene-peptide-steroid 
covalent hybrids. Tetrahedron 2014;70:8564-8570. Copyright (2014) Elsevier Ltd. 
 
Figure 14. Fluorescence micrographs of neuroblastoma cells incubated with (green) Baa-
Lys(FITC)-(Lys)2-Arg-Lys-Val-OH and (blue) DAPI. Scale bar = 150 m. Reproduced with 
permission from Yang J, Wang K, Driver J, Yang J, Barron AR. The use of fullerene substituted 
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phenylalanine derivatives as a passport through cell membranes. Org Biomol Chem 
2007;5:260-266. Copyright (2007) Royal Society of Chemistry. 
 
Figure 15. Cell line proliferation for neuroblastoma cell lines (a) IMR-32 and (b) LAN-1, and 
(c) breast cancer cell line MCF-7 in the presence of DMSO (red), Baa-Lys(FITC)-Asn-Asp-
Leu-Arg-Ser-Ser-Phe-Leu-Thr-Leu-Arg-Asp-His-Val (Baa-1) (blue) and Baa-Lys(FITC)-
Asn-Asp-Leu-Arg-Ser-Ala-Phe-Ala-Thr-Leu-Arg-Asp-His-Val (yellow) (43).  
 
Figure 16. Structure of [60]fullereo-peptide with oxidized methionine (30) 
 
Figure 17. Structure of [60]fullerene derivative of the of the pentapeptide sequence H-Thr-Thr-
Asn-Tyr-Thr-OH (24).  
 
Figure 18. Structure of the C60-amino acid-based peptides synthesized and used in the HIV-1 
PR inhibition study (37). 
 
Figure 19. IFD position of Fmoc-Phe(4-aza-C60)-Lys3-OH into the HIV-1 PR active site. 
Dashed blue lines indicate H-bonds. Reproduced with permission Strom TA, Durdagi S, Ersoz 
SS, Salmas RE, Supuran CT, Barron AR, Fullerene-based inhibitors of HIV-1 protease. J 
Peptide Sci 2015;21:862-870. Copyright (2015) John Wiley & Sons, Ltd. 
 
Figure 20. Confocal scanning microscopy images of intact skin dosed with Baa-Lys(FITC)NLS 
for 8 h (FITC = fluorescein isothiocyanate; NLS = Pro-Lys-Lys-Lys-Arg-Lys-Val). Top row: 
confocal-differential interference contrast (DIC) channel image shows an intact stratum 
corneum (SC) and underlying epidermal (E) and dermal layers (D). Middle row: Baa-
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Lys(FITC)-NLS fluorescence channel (green) and confocal-DIC channel show [60]fullerene 
penetration through the epidermal and dermal layers of skin. Bottom row: fluorescence intensity 
scan showing Baa-Lys(FITC)-NLS penetration. All scale bars represent 50 μm. Reproduced 
with permission from Rouse JG, Ryman-Rasmussen JP, Yang J, Barron AR, Monteiro-Riviere 
NA, Effects of mechanical flexion on the penetration of fullerene amino acid-derivatized 
peptide nanoparticles through skin. Nano Lett 2007;7:155-160. Copyright (2007) American 
Chemical Society.  
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